Ascletis Pharma Inc

Ascletis Pharma Inc has a total equity of CNY 19.34 billion and total liabilities of CNY 1.32 billion, resulting in a current ratio of 15.05, which is significantly higher than the industry median. The company's liquidity position is characterized as medium, with a negative net cash position after subtracting total debt. The company's free cash flow is negative at CNY -344.24 million, indicating ongoing cash outflows from operations. The company's profitability metrics are negative, with a return on equity of -18.61% and a return on assets of -17.41%. These figures are well below the industry median for pharmaceutical companies, which typically exhibit positive returns. The company's operating income is CNY -359.21 million, and its net income is CNY -359.88 million, reflecting significant operational losses. Ascletis Pharma Inc's revenue is primarily concentrated in its core pharmaceutical business, with no disclosed geographic revenue breakdown. The company's business is heavily dependent on the success of its drug pipeline, particularly in the treatment of chronic hepatitis B. There is no indication of significant diversification across product lines or geographic regions. The company's growth trajectory is uncertain, with no disclosed revenue growth in the most recent fiscal year. The company's operating cash flow is negative at CNY -416.78 million, and its capital expenditures are CNY -1.97 million, indicating minimal investment in new projects. Analysts have provided a mean price target of CNY 23.86, with a median of CNY 23.86, suggesting limited upside potential in the near term. The company's risk profile is characterized by medium liquidity risk and low dilution risk. The key risk flag is the negative net cash position after subtracting total debt, which could impact the company's ability to fund operations without external financing. The company has not issued any new shares recently, and there is no indication of dilution pressure in the near term. Recent events include the company's continued focus on its hepatitis B drug pipeline, with no major product launches or regulatory approvals disclosed in the latest financial report. The company's operating losses and negative cash flows suggest ongoing challenges in achieving profitability. There are no recent filings or transcripts indicating significant changes in the company's strategic direction.